Aleksandra Filipovic, Chief Medical Officer at Gallop Oncology, shared PureTech Health’s post on LinkedIn, adding:
“I have dedicated my career to helping people with cancer, both as a practicing oncologist and as a drug developer. That commitment drives my work every day and is why I’m encouraged by the Phase 1b data announced today from our LYT-200 program at Gallop Oncology.
These results provide important insight across two patient populations—relapsed/refractory high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia—where there remains a significant need for new treatment options. I’m incredibly proud of the team for the thoughtful and rigorous execution of this trial and energized by the potential to make a meaningful difference for patients.
We look forward to engaging with the FDA as we define the next steps, with the goal of advancing new treatment options for those who need them most.
Grateful to the patients, investigators, our incredible PureTech Health team and all other teams who made this work possible.”
Quoting PureTech Health’s post:
“We’re pleased to share positive topline data from the Phase 1b trial of LYT-200 in relapsed/refractory (R/R) high-risk myelodysplastic syndromes (MDS) and R/R acute myeloid leukemia (AML).
The data demonstrate clinical activity and favorable tolerability in heavily pretreated patients and support advancing LYT-200 first in R/R HR-MDS, where the need for new treatment options remains significant. Our Founded Entity, Gallop Oncology, intends to engage with the FDA to discuss next steps.
We extend our sincere gratitude to the investigators, participants, and caregivers who made this trial possible.”
Proceed to the video attached to the post.
More posts featuring Aleksandra Filipovic.